| 000 | 00963 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250513061204.0 | ||
| 264 | 0 | _c19930520 | |
| 008 | 199305s 0 0 eng d | ||
| 022 | _a0006-3223 | ||
| 024 | 7 |
_a10.1016/0006-3223(93)90301-s _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMattes, J A | |
| 245 | 0 | 0 |
_aShould DSM-III-R GAD criteria be used for studies of anxiolytics? _h[electronic resource] |
| 260 |
_bBiological psychiatry _cFeb 1993 |
||
| 300 |
_a302-3 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Anxiety Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAnxiety _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 | _aReproducibility of Results |
| 700 | 1 | _aKonig, P H | |
| 773 | 0 |
_tBiological psychiatry _gvol. 33 _gno. 4 _gp. 302-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0006-3223(93)90301-s _zAvailable from publisher's website |
| 999 |
_c8096439 _d8096439 |
||